Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AstraZeneca
Genmab
AstraZeneca
Eli Lilly and Company
M.D. Anderson Cancer Center
Qilu Pharmaceutical Co., Ltd.
AstraZeneca
AstraZeneca
University of Oklahoma
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Eli Lilly and Company
AstraZeneca
GlaxoSmithKline
Merck Sharp & Dohme LLC
Blueprint Medicines Corporation
Avenzo Therapeutics, Inc.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Bio-Thera Solutions
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
GlaxoSmithKline
Seoul National University Hospital
University of Maryland, Baltimore
Merck Sharp & Dohme LLC
Mario Negri Institute for Pharmacological Research
Ohio State University Comprehensive Cancer Center
Inspirna, Inc.
Ohio State University Comprehensive Cancer Center
Huabo Biopharm Co., Ltd.
Washington University School of Medicine
Peking Union Medical College Hospital
Leiden University Medical Center
Merck Sharp & Dohme LLC
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
NETRIS Pharma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Zhongnan Hospital
Huazhong University of Science and Technology
University of Oklahoma
Sun Yat-sen University
Fujian Cancer Hospital
Loyola University
National Cancer Institute, Naples